z-logo
open-access-imgOpen Access
FDTD Simulation of Magnetic Field Distribution in Normal and Blood Cancer for Treatment
Author(s) -
Vinda Zakiyatuz Zulfa,
Ulya Farahdina,
Muhammad Firdhaus,
Ihwanul Aziz,
Nasori Nasori,
Endarko Endarko,
D Darsono,
Agus Rubiyanto
Publication year - 2021
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1951/1/012061
Subject(s) - magnetic field , finite difference time domain method , electrode , materials science , biomedical engineering , nuclear magnetic resonance , medicine , chemistry , optics , physics , quantum mechanics
Non-invasive cancer treatment has the potential to eliminate infection and scar formation associated with surgery to minimize side effects. Light stimulation can use for treatment to increase efficiency, reduce treatment costs, eliminate infection, etc. Magnetic fields can improve blood circulation in tissues and stimulate the body’s metabolism. The magnetic field can induce joule heating and expand the blood vessels of cancerous tumors. These blood vessels increase the possibility of excess oxygen to enter the tumor creating obstacles to the survival of oxygen-rich cancers. In this study, we investigate finite difference times domain (FTDT) simulation of magnetic field in normal and blood cancer. The low frequency with range 10-10 6 is used in this study. The maximum magnetic field for normal blood and CLL1 is 400 nm and 250 nm in 125 cm electrode size. While for 50 nm electrode size, the maximum magnetic field in normal blood and CLL 1 is 400 nm and 300 nm. But there The maximum magnetic field for normal blood and CLL1 is 400 nm and 250 nm in 125 cm electrode size. While for 50 nm electrode size, the maximum magnetic field in normal blood and CLL 1 is 400 nm and 300 nm. But there is no peak for blood cancer in final stage CLL2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here